HotSpot Therapeutics, Inc., a Boston-based biotechnology company, announced on Wednesday that it is presenting its initial clinical data from the monotherapy dose-escalation portion of the Phase one study of HST-1011 in a Proffered Paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, scheduled from 13 September to 17 September 2024, in Barcelona, Spain.
HST-1011 is an oral and selective inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B).
The clinical data is being revealed with a focus on safety, exposure, and pharmacodynamic measures.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial